H.C. Wainwright reiterated coverage of Enlivex Therapeutics with a rating of Buy and set a new price target of $33.00 from $22.00 previously

As a Gold Sponsor of the Paris event, Enlivex will host a curated dinner today for leading institutional asset managers, allocators, and digital asset investors Nes-Ziona, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, ", Enlivex", or the ", Company", )), a quality longevity company powered by a prediction markets treasury, today announced that it is a Gold Sponsor of Proof of Talk 2026, taking place June 2-3, 2026, at the Louvre Palace and Musée des Arts Décoratifs in Paris. Proof of Talk is one of Europe's leading institutional summits on digital assets, convening approximately 2,500 senior decision-makers across asset management, banking, policy, and Web3, with a

The data were selected for an oral podium presentation at EULAR and will be presented by Prof. Philip Conaghan, a globally recognized key opinion leader in osteoarthritis Nes-Ziona, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, ", Enlivex", or the ", Company", )), a quality longevity company powered by a prediction markets treasury, today announced that it will present at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, taking place June 3-7, 2026, in London, UK. The presentation will feature extended 3-month and 6-months clinical data, as well as comprehensive mechanistic and pharmacological characterization data,

As of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.16 billion.Separately, the Rain Foundation recently announced the appointment of five industry leaders to its advisory board, supporting the next phase of growth of the Rain protocol, the primary digital asset in Enlivex's prediction markets treasury strategy. Nes-Ziona, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, ", Enlivex", or the "Company", )), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of May 27, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately

Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and Kalshi1.Rain's Upgraded Positioning as a Top-3 Prediction Market and the Scale of its Capital Deployment Reinforce the Potential of the Enlivex Treasury StrategyAs of May 26, 2026, Enlivex's RAIN token holdings were 79,568,550,005 tokens, with a total value of approximately $919 million. In addition, Enlivex holds an option to acquire up to 271,372,418,179 RAIN tokens from the Rain Foundation, at a purchase price of $0.0033 per RAIN token. The option's expiration date is Dec. 31, 2027. The option

Enrollment milestone follows FDA IND clearance received in March 2026 and Danish Medicines Agency (DKMA) approval received in April 2026 Nes-Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the dosing of the first patient at a United States clinical site in the Phase 2b clinical trial of Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). The global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial is designed to evaluate the efficacy and safety

Nes-Ziona, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today announced that it has received a notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq"), stating that the  closing bid price of the Company's ordinary shares during the 30 consecutive business days prior to the date of the Notice did not meet the $1.00 minimum bid price requirement in accordance with Nasdaq Listing Rule 5550(a)(2). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with an initial period of 180 calendar days, or until November 9, 2026, to regain complia

The listing on one of the world's largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex's primary digital treasury asset Nes-Ziona, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today reported that its treasury asset, the RAIN token, has been listed on the HTX cryptocurrency exchange, effective April 29, 2026. The listing marks an important step forward for RAIN, significantly increasing its accessibility, global reach, and token liquidity. HTX (formerly Huobi) is a leading global cryptocurrency exchange serving over 160 c

New acquisitions from Rain Foundation underlines Enlivex's disciplined prediction markets treasury strategy Nes-Ziona, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today announced that as of April 27, 2026, Enlivex's total RAIN holdings increased to 78,819,756,062 tokens, which had a total value of $567 million1. Oren Hershkovitz, Ph.D, CEO of Enlivex, said, "Securing additional RAIN at a material discount to recent market prices reflects our disciplined treasury strategy that we believe may potentially create additional shareholder value. Our approach is supporte

Nes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2026 World Congress on Osteoarthritis, taking place April 23-26, 2026, in West Palm Beach, Florida, USA. The presentations will feature 3-month and 6-month endpoints clinical data from the Phase IIa (NCT06233474) for Allocetra™ in patients with moderate-to-severe knee osteoarthritis (KOA).  The Phase IIa data demonstrated clinically meaningful and statistically significant improvement of the Al

·      Approval by the Danish Medicines Agency (DKMA) for enrolling patients in Denmark follows the recently announced FDA clearance to initiate the Phase 2b study in the United States. Nes-Ziona, Israel, April 21, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that it has received Clinical Trial Application (CTA) approval by the Danish Medicines Agency (DKMA) for the Phase 2b trial of Allocetra™, the Company's clinical-stage immunotherapy, for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). The planned global, multicenter, randomized, double-blind,

3 - Enlivex Ltd. (0001596812) (Issuer)

3 - Enlivex Ltd. (0001596812) (Issuer)

3 - Enlivex Ltd. (0001596812) (Issuer)

3 - Enlivex Ltd. (0001596812) (Issuer)

3 - Enlivex Ltd. (0001596812) (Issuer)

3 - Enlivex Ltd. (0001596812) (Issuer)

3 - Enlivex Ltd. (0001596812) (Issuer)

6-K - Enlivex Ltd. (0001596812) (Filer)

6-K - Enlivex Ltd. (0001596812) (Filer)

6-K - Enlivex Ltd. (0001596812) (Filer)

6-K - Enlivex Ltd. (0001596812) (Filer)

424B3 - Enlivex Ltd. (0001596812) (Filer)

F-3 - Enlivex Ltd. (0001596812) (Filer)

6-K - Enlivex Ltd. (0001596812) (Filer)

6-K - Enlivex Ltd. (0001596812) (Filer)

6-K - Enlivex Ltd. (0001596812) (Filer)

20-F - Enlivex Ltd. (0001596812) (Filer)

Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, "Enlivex" or "the Company")), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11:00 am ET. Shai Novik, Executive Chairman of Enlivex, will provide an update on the Company's plans following its recently closed $212,000,000 private placement. Mr. Novik will discuss the launch of Enlivex's digital asset treasury strategy built around RAIN token accumulation as well as the Company's plans to continue to advance the clinical development of AllocetraTM. Virtual Fireside Chat Details Date: December 11, 2025Time: 11:00 am ETRegistration Link:https://shorturl

ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c

ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Enlivex Therapeutics: https://www.redchip.com/assets/access/enlv_accessBiotricity: https://www.redchip.com/assets/access/btcy_accessOren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update.

Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will host a conference call and webcast on April 12, 2024, at 8:30am ET (15:30 IL time) to discuss topline results from its Phase II trial of Allocetra™ in patients with sepsis, in which 120 patients enrolled.  During the call, members of Enlivex's leadership team will discuss the results. A live Q&A session will follow the Company's prepared remarks. Webcast Details To register for the live webcast, visit https://redchip.zoom.us/webinar/register/WN_-na6Jb4uRG6b3N59eRQRaQ ABOUT ENLIVEX En

ORLANDO, FL / ACCESSWIRE / March 22, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and Unusual Machines Inc. (NYSE:UMAC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Enlivex Therapeutics: https://www.redchip.com/assets/access/enlv_accessUnusual Machines: https://www.redchip.com/assets/access/umac_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV t

SC 13G - Enlivex Therapeutics Ltd. (0001596812) (Subject)

As of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.16 billion.Separately, the Rain Foundation recently announced the appointment of five industry leaders to its advisory board, supporting the next phase of growth of the Rain protocol, the primary digital asset in Enlivex's prediction markets treasury strategy. Nes-Ziona, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, ", Enlivex", or the "Company", )), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of May 27, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately

Enlivex Announced today $212,000,000 private placement to initiate world's first prediction markets digital asset treasury strategy, via RAIN token accumulation NESS ZIONA, Israel, Nov. 24, 2025 /PRNewswire/ -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV) today announced the appointment of Mr. Matteo Renzi, former Prime Minister of Italy, to the board of directors at Enlivex, effective November 24th. 2025. Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) for the purchase and sale of 212,000,000 ordinary shares (or ordinary share equi

- Upon the closing of the private placement, Enlivex will adopt the world's first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN is a fully decentralized predictions and options protocol that redefines predictive market ecosystems and provides a powerful platform for on-chain market creation - built for transparency, automation, and community participation. - Mr. Matteo Renzi, former Prime Minister of Italy, will be appointed to the Enlivex Board of Directors following closing of the private placement. - Enlivex to continue clinical development of Allocetra™, a potentially game-changing knee osteoarthritis therapeutic, a growing market w

YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound. "We are delighted to welcome Shmulik, a distinguished industry executive, to our team. Dr. Hess joins MediWound during a crucial phase of expansion as we diligently implement our global strategy. Given Shmulik's outstanding track record in international o

Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategyFormer EVP and CFO of Epizyme and Senior Biotech Investment Banker at Credit Suisse, Wells Fargo Securities and RBC Capital MarketsLed financing, partnering and M&A biopharmaceutical transactions in excess of $13 billion Nes-Ziona, Israel, April 17, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Andrew Singer to its Board of Directors. Mr. Singer brings more than 25 years of experience in biotechnology, corporate finan

Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is

Dr. Galamidi joins Enlivex after 10 years at Gamida Cell Ltd., where she most recently served as Vice President of Clinical Development At Gamida Cell, Dr. Galamidi led clinical development for omidubicel, a cell therapy that successfully completed Phase III in 2020A Biologics License Application (BLA) rolling submission process with the FDA for omidubicel was initiated recently, indicated for patients with blood cancers needing bone marrow stem cell transplant Nes Ziona, Israel, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Einat Galamidi, M.D. has join

Initiated dosing in placebo-controlled Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with ARDS Received authorization to expand ongoing sepsis and COVID-19 trials into Spain Initiated design and construction process for a new cGMP AllocetraTM manufacturing plant Nes Ziona, Israel, Nov. 22, 2021 (GLOBE NEWSWIRE) -- -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it filed its financial results and related discussion for the third quarter ended September 30, 2021 with the SEC on November 19, 2021. "We are advancing towards 2022 with

Publication follows the Israeli Ministry of Health's appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines Nes-Ziona, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that its Chief Scientific Officer, Prof. Dror Mevorach, M.D., and several co-authors published a foundational peer reviewed paper in The New England Journal of Medicine, the world's most widely read, cited, and influential general medical periodical. The paper, entitled "Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel